ENCell

이엔셀 · 456070

Health Care Pharmaceuticals · KOSDAQ

Small-cap

Market cap US$76.8M (₩106B)

Overview

ENCell is a South Korean biotech company focused on cell therapy, treatments that use living cells to address disease, listed on KOSDAQ, Korea's tech and small-cap stock exchange.

Its products are intended for use in medical and clinical settings, placing it within the broader biopharmaceutical supply chain. ENCell has no subsidiaries and operates as a standalone entity.

Summary is AI-generated and may contain errors · figures from DART filings

Financials

Source: DART · FY ending Dec · latest FY2025

Revenue · FY2025

US$3.8M

▼ −27.1% YoY

Operating profit · FY2025

−US$13M

Loss widened

Net income · FY2025

−US$11.7M

Loss widened

Revenue, operating profit and net income by fiscal year (USD; KRW in parentheses).
Metric	FY2024	FY2025
Revenue	US$5.2M(₩7.2B)	US$3.8M(₩5.3B)
Operating profit	−US$11.4M(−₩15.7B)	−US$13M(−₩17.9B)
Net income	−US$11M(−₩15.2B)	−US$11.7M(−₩16.1B)

Revenue

FY2024US$5.2M
FY2025US$3.8M

Operating profit

FY2024−US$11.4M
FY2025−US$13M

Net income

FY2024−US$11M
FY2025−US$11.7M

Key ratios (FY2025)

ROE

-40.9%

Debt/Eq

61.7%

Op. margin

-340.4%

Net margin

-306.3%

Rev. YoY

▼ −27.1%

Price charts coming soon

Interactive price history isn't here yet. Would you use it?